Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.39
$0.03(2.48%)
At close: 4:00 PM EDT
$1.39
$0.03(2.48%)
Day’s Range― - ―
52-Week Range$0.64 - $1.87
Previous Close$1.19
Volume745.95K
Average Volume (3M)N/A
Market Cap
$143.46M
Enterprise Value$42.95
Total Cash (Recent Filing)$105.69M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding103,206,210
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside187.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$31.44M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsThe platform retains attractive underlying product and service economics. Sustained high gross margins provide a foundation for future operating leverage if instrument placements, consumables usage, and partner activity produce durable revenue growth.
Strong Balance SheetSubstantial liquidity and negligible leverage reduce refinancing risk and give MaxCyte time to invest in platform development, support customers, and pursue partnerships while revenue recovers without relying heavily on external financing.
Strategic Partner And Platform ExpansionThe Genentech agreement broadens MaxCyte's reach across research, clinical development, and manufacturing, while the wider partner base supports recurring technology access and potential milestones or royalties as programs advance.
Bears Say
Deep Operating UnprofitabilityGross profitability has not yet offset the company's operating cost base. Persistent negative EBIT and EBITDA indicate that MaxCyte still lacks sufficient scale, making sustainable earnings dependent on revenue growth and continued expense discipline.
Negative And Deteriorating Cash FlowThe business continues to consume cash rather than self-finance operations, and worsening free cash flow increases execution pressure. Although liquidity is strong, prolonged losses could eventually constrain investment or require additional capital.
Revenue Contraction And Margin PressureDeclines across core revenue streams weaken confidence in near-term operating leverage. The lower margin also shows that product mix can affect profitability, while recovery depends on renewed instrument demand, processing activity, and partner programs.
MaxCyte News
MXCT FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was $0.64 and its highest was $1.86 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is $143.46M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 77 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.01.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 103,206,210 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 9.449%.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (187.77% Upside)
$4.00 (187.77% Upside)
Blogger Sentiment
Neutral
MXCT Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 10.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.96%
Trailing 12-Months
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company that has stabilized near-term revenue, materially reduced operating expenses, and strengthened its strategic positioning through a large enterprise partnership (Genentech), while maintaining a strong balance sheet. These positives were offset by notable year-over-year revenue declines, gross margin pressure due to product mix, and prior partner/program headwinds. Management reiterated guidance and expects a return to growth in H2 2026, with further upside tied to SPL royalties and instrument adoption.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
▲(187.77% Upside)
Ownership Overview
2.20% Insiders
10.87% Mutual Funds
29.41% Other Institutional Investors
53.35% Public Companies and
Individual Investors